Trimethobenzamide hydrochloride is a sterile solution for intramuscular injection. Each 1 mL contains 100 mg trimethobenzamide hydrochloride compounded with 0.45% phenol as preservative, 0.5 mg sodium citrate anhydrous and 0.2 mg citric acid anhydrous as buffers, and 0.1 mg edetate disodium as stabilizer in Water for Injection. pH is adjusted with sodium hydroxide or hydrochloric acid.
Trimethobenzamide is indicated for the following:
For the treatment of postoperative nausea and vomiting and nausea associated with gastroenteritis.
Media Articles Related to Trimethobenzamide
FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy
Source: Cancer / Oncology News From Medical News Today [2014.10.14]
The U.S. Food and Drug Administration has approved Akynzeo (netupitant and palonosetron) to treat nausea and vomiting in patients undergoing cancer chemotherapy.
Nausea and Vomiting
Source: MedicineNet Anaphylaxis Specialty [2014.07.09]
Title: Nausea and Vomiting
Category: Diseases and Conditions
Created: 1/31/2005 8:21:00 AM
Last Editorial Review: 7/9/2014 12:00:00 AM
FDA Gives Nod to Eisai's Antiemetic Combo
Source: MedPage Today Oncology/Hematology [2014.10.10]
(MedPage Today) -- Fixed-dose NEPA (Akynzeo) prevented chemotherapy-induced nausea and vomiting in the acute and late phases
Published Studies Related to Trimethobenzamide
A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraines. [2006.06]
BACKGROUND: Although various classes of medication are used to treat acute migraine in the emergency department (ED), no treatment offers complete pain relief without side effects or recurrence of headache. Consequently, even though several antiemetic medications as well as SQ sumatriptan have demonstrated efficacy and tolerability for the ED treatment of migraine, there remains a need for more effective parenteral therapies. Open-label studies suggest that the combination of trimethobenzamide and diphenhydramine (TMB/DPH) may provide effective relief in a high proportion of migraineurs. OBJECTIVE: To test the hypothesis that ED patients with acute migraine, given intramuscular TMB/DPH, would have a larger reduction in their pain scores than patients given SQ sumatriptan... CONCLUSIONS: SQ sumatriptan is probably superior to TMB/DPH for treating the pain of acute migraine at 2 hours. However, TMB/DPH was well-tolerated, efficacious, and relieved pain comparably to sumatriptan at 24 hours. TMB/DPH might have a role in select populations in which sumatriptan is contraindicated or likely to be ineffective.
Clinical Trials Related to Trimethobenzamide
Safety/Efficacy of Tigan´┐Ż to Control Nausea/Vomiting Experienced During Apokyn´┐Ż Initiation and Treatment [Recruiting]
The purposes of the study are to determine:
i. To assess the efficacy of Tigan« (trimethobenzamide) in preventing nausea and vomiting
when initiating therapy with Apokyn« (apomorphine)
ii. To determine the optimal duration for continuation of Tigan« following initiation of
iii. To assess the safety of Tigan« in combination with Apokyn«
iv. To characterize the pharmacokinetic (PK) profile of apomorphine in subjects treated
concomitantly with and without Tigan┬«
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) [Recruiting]
PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD) [Recruiting]
This study will explore the brain in men with and without attention deficit hyperactivity
disorder (ADHD). It will use positron emission tomography (PET) and magnetic resonance
imaging (MRI) to study brain function and nerve cell communication involving phospholipids
(fatty molecules that make up the covering of nerve cell fibers in the brain and are
involved in communication between the cells). It will also look at how nerve cell
communication is related to blood flow. In particular, the study will explore communication
through the dopamine system, which is one of the main neurotransmitter systems in the brain
involved in ADHD.
Healthy men and men with ADHD between 18 and 55 years of age may be eligible for this study.
Participants undergo the following procedures:
" Medical history and psychiatric and medical evaluation, including blood and urine tests.
" MRI scan. This test uses a strong magnetic field and radio waves to obtain images of the
brain. The subject lies still on a table that slides into the scanner (a metal cylinder)
during the scanning.
" PET scanning. The subject lies on the scanner bed with his head held still using a special
facemask. A catheter (plastic tube or needle) is placed in an artery to collect blood
samples and in a vein to inject radioactive isotopes for measuring blood flow and
phospholipid metabolism. Scans are done after an injection of a saline solution and again
after injection of apomorphine, a medication that turns on dopamine receptors in the brain.
The injections are given under the skin of the abdomen, about one and a half hours apart....
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Trimethobenzamide has an overall score of 9. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Trimethobenzamide review by 41 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || Vertigo|
|Dosage & duration:|| || 300mg taken 1x 8 hours for the period of 4-5 days|
|Other conditions:|| || None|
|Other drugs taken:|| || Meclizine|
|Benefits:|| || The trimethobenzamide significantly reduced nausea and brought it down to a perceptible but comfortable level.|
|Side effects:|| || None.|
|Comments:|| || After being diagnosed with temporary vertigo, I was given prescriptions for this plus Meclizine for dizziness. The two combined brought the vertigo completely under control. There were no side effects. I took the medication as originally prescribed for two days and then, at my doctor's suggestion, reduced the amount to as-needed. The trimethobenzamide made it possible to eat normally, with no uncomfortable feelings of nausea.|